Product Description
GLIA was developing gl-101, a Ocular,Topical agent for patients under ongoing treatment with glaucoma medications. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02656394)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Ocular,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GLIA
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Glaucoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GL-1 | P2 |
Completed |
Glaucoma |
2017-12-04 |